Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials

OncoTargets and Therapy
Bingkun XiaoDezhi Zhang

Abstract

Bevacizumab and ramucirumab are antiangiogenic monoclonal antibodies, which target vascular endothelial growth factor-A and vascular endothelial growth factor receptor-2, respectively, used in various cancers. Bleeding events have been described with these two agents. We conducted an up-to-date meta-analysis to determine the relative risk (RR) associated with the use of antiangiogenic monoclonal antibodies, bevacizumab and ramucirumab. This meta-analysis of randomized controlled trials was performed after searching PubMed, American Society for Clinical Oncology Abstracts, European Society for Medical Oncology Abstracts, and the proceedings of major conferences for relevant clinical trials. RR and 95% CIs were calculated by random-effects or fixed-effects models for all-grade and high-grade bleeding events related to the angiogenesis inhibitors. Eighty-five randomized controlled trials were selected for the meta-analysis, covering 46,630 patients. The results showed that antiangiogenic monoclonal antibodies significantly increased the risk of all-grade (RR: 2.38, 95% CI: 2.09-2.71, p<0.00001) and high-grade (RR: 1.71, 95% CI: 1.48-1.97, p<0.00001) bleeding compared with control arms. In the subgroup analysis, bevacizumab signifi...Continue Reading

Citations

Feb 20, 2020·Surgical Case Reports·Hiroki OharaKazuhiro Imamura
Apr 15, 2020·Dose-response : a Publication of International Hormesis Society·Longqing Wang, Xiaofeng Sun
Nov 3, 2020·Expert Review of Gastroenterology & Hepatology·Hui Li
Nov 19, 2020·Cancer Management and Research·Guohe LinNianfei Wang
May 3, 2021·Journal of Translational Medicine·Jingyao CaiZeng Ling
May 1, 2021·Journal of Thrombosis and Haemostasis : JTH·Nathan Watson, Hanny Al-Samkari
Jun 29, 2021·Current Physical Medicine and Rehabilitation Reports·Jasmine Y ZhengMitra D McLarney

❮ Previous
Next ❯

Software Mentioned

PRISMA
Review Manager

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.